youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
GRAL:NASDAQ
Grail Inc
$133.76
arrow_downward
-6.74%(-9.67) 1D
$133.76
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$148.53
High
$149.00
Low
$132.13
Mkt. cap
5.97B
Avg. vol.
1.24M
Volume
0.00
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$148.53
High
$149.00
Low
$132.13
Mkt. cap
5.97B
Avg. vol.
1.24M
Volume
0.00
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
marketscreener.com
·
26 minutes ago
S&P 500 index fell sharply after Stockholm exchange close Monday
BigGo Finance
·
12 minutes ago
Nasdaq Vice Chairman Warns: Taiwan Stocks Climb to World's Fourth Largest, but 79% AI Exposure Tops the Globe
Quantisnow
·
49 minutes ago
Pershing Square USA, Ltd. Releases Third Quarter 2026 Portfolio Review
MarketWatch
·
7 hours ago
Nasdaq Inc. stock outperforms competitors on strong trading day
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com
Analyst ratings
Based on 10 analysts giving stock ratings to GRAL in the past 3 months
Buy
Buy
6
Hold
4
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for GRAL in the last 3 months.
Highest
Current $133.76
$180.00 (+34.57%)
Average
$128.67 (-3.81%)
Lowest
$56.00 (-58.13%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Kallum Titchmarsh Morgan Stanley | Hold | Maintained | $120.00 | -10.3% | 10/13/2026 |
Daniel Brennan TD Cowen | Buy | Maintained | $180.00 | +34.6% | 10/13/2026 |
Evie Koslosky Goldman Sachs | Hold | Maintained | $120.00 | -10.3% | 10/05/2026 |
Doug Schenkel UBS | Buy | Reiterated | $175.00 | +30.8% | 10/02/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $155.00 | +15.9% | 10/01/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Reiterated | $150.00 | +12.1% | 09/28/2026 |
Robert Bamberger Robert W. Baird | Buy | Maintained | $118.00 | -11.8% | 09/22/2026 |
Bradley Bowers Mizuho Securities | Buy | Maintained | - | - | 09/22/2026 |
Dan Leonard RBC Capital | Hold | Maintained | $84.00 | -37.2% | 09/21/2026 |
Unknown Analyst UBS | Buy | Initiated | $105.00 | -21.5% | 09/13/2026 |
David Westenberg Piper Sandler | Hold | Maintained | $56.00 | -58.1% | 08/06/2026 |
Paige Chamberlain Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Unknown Analyst Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $70.00 | -47.7% | 05/06/2026 |
Next call in 39:42:02
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$1.90
Revenue / Est. (USD)
- / 44.21M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 36.19M | 43.60M | 40.78M | 44.69M |
Cost of goods sold | 16.45M | 21.26M | 21.62M | 23.78M |
Cost of revenue | 16.45M | 21.26M | 21.62M | 23.78M |
Research and development expenses | 48.65M | 46.90M | 48.02M | 47.43M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 62.91M | 66.38M | 73.44M | 88.36M |
Operating expense | 145.03M | 146.75M | 154.93M | 169.27M |
Total operating expenses | 161.48M | 168.01M | 176.55M | 193.05M |
Operating income | -125.29M | -124.41M | -135.76M | -148.36M |
Other non operating income | - | -993.00K | - | - |
EBT including unusual items | -118.72M | -116.52M | -127.52M | -166.71M |
EBT excluding unusual items | -118.72M | -116.52M | -127.52M | -141.28M |
Income tax expense | -29.74M | -17.34M | -34.34M | -56.46M |
Effective tax rate | 25.05% | 14.88% | 26.93% | 33.87% |
Other operating expenses | - | - | - | - |
Net income | -88.98M | -99.18M | -93.19M | -110.25M |
Net profit margin | -245.83% | -227.48% | -228.48% | -246.71% |
Earnings per share | -2.46 | -2.44 | -1.37 | -1.34 |
Interest and investment income | 6.11M | 7.96M | 7.99M | 7.23M |
Interest expense | - | - | - | - |
Net interest expenses | 6.11M | 7.96M | 7.99M | 7.23M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -86.31M | -85.50M | -96.97M | -109.67M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events